Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PAC001, TOUR006
Pacibekitug · 1 trial · 1 indication
3-point Coronary major adverse cardiovascular events (3P-Coronary-MACE), defined as a composite of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), and urgent coronary revascularization
| Arm | Type | Description |
|---|---|---|
| Pacibekitug | EXPERIMENTAL | pacibekitug s.c. |
| Placebo | PLACEBO_COMPARATOR | Placebo s.c. |
| Name | Type | Description |
|---|---|---|
| Pacibekitug | DRUG | pacibekitug s.c. |
| Placebo | DRUG | Placebo s.c. |
Inclusion Criteria: The key inclusion criteria are as follows: * Adults aged ≥ 18 years at the time of informed consent form (ICF) signature. * Diagnosis of spontaneous (type 1) MI based on medical records and the Investigator's judgment. Patients must be either: 1. ≤ 30 days from the index MI ...
Pacibekitug is an investigational biologic drug being developed by Novartis AG for patients who have had a myocardial infarction, commonly called a heart attack. It is in Phase 3 clinical development and is designed to be studied for its effect on major cardiovascular events after a myocardial infarction.
Pacibekitug is being developed for use in patients after a myocardial infarction, with the goal of assessing its effect on major cardiovascular events. It is investigational and is being studied in a Phase 3 trial; it is not yet established as a treatment for this population.
Pacibekitug is developed by Novartis AG, which trades under the ticker NVS. Novartis is the sponsor of the Phase 3 program evaluating pacibekitug in patients following a myocardial infarction.
Pacibekitug is in Phase 3 clinical development. It is an investigational biologic and is not approved; the Phase 3 program is evaluating its effect on major cardiovascular events in patients after a myocardial infarction.
Pacibekitug is being studied in the Phase 3 trial NCT07938411, titled A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction. The trial is not yet recruiting, plans to enroll 10,000 participants aged 18 years and older of all sexes, and is randomized, double-blind, and placebo-controlled.